Wyeth, Progenics drug misses goal in late-stage trial

ibtimes.com     May 22, 2008            

COLLEGEVILLE, Pa. (AP) - Wyeth and Progenics Pharmaceuticals Inc. said Thursday that early results from a late-stage trial of their drug Relistor did not meet its goal in restoring gastrointestinal function following surgery to the intestine. The study, in a condition known as post-operative... [read full story]                    

FULL COVERAGE

Wyeth and Progenics report preliminary results from clinical trials of Relistor

orglex.com     May 24, 2008          

Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have reported preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor.[...] [ Pharmaceutical Business Review ] -...                    

comments

Wyeth and Progenics report preliminary results from clinical trials of Relistor

pharmaceutical-business-review.com     May 24, 2008          

Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have reported preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor. The first of these studies, a Phase II trial, evaluated the effects of an oral...                    

comments